Civica

What Civica does

Civica is a Delaware-incorporated nonprofit pharmaceutical company founded in 2018 and headquartered in Lehi, Utah, created by leading U.S. health systems and philanthropies to address chronic generic drug shortages and predatory pricing. The company supplies more than 70 essential sterile injectable generic medications to over 1,400 hospitals through 60 health system members that collectively represent more than 30% of U.S. licensed hospital beds, supporting care for approximately 95 million patients. Civica's core technology is a U.S.-based manufacturing capability centered on the $124.5 million, 140,000+ square-foot Petersburg, Virginia fill-finish facility equipped with Groninger and SKAN isolator technology, disposable systems, and three production lines (vials, pre-filled syringes, pre-filled pen cartridges) capable of producing over 200 million units annually.

The business operates on a cost-plus pricing model with six months of safety stock and direct contracting that bypasses traditional rebate and middleman structures. Civica monetizes through hospital membership contracts (Civica Rx), a Federal Supply Schedule contract with the U.S. Department of Veterans Affairs, and a consumer/outpatient arm (CivicaScript) that distributes affordable generics and biosimilars to health plans, PBMs, and retail pharmacies—including insulin glargine-yfgn at $45 per five-pen box and ustekinumab-aauz biosimilar at $575-$985 per 12-week supply. The Civica Foundation, a 501(c)(3) subsidiary, channels philanthropic support for programs such as affordable insulin and the Rural Hospital Program. Partnerships span the biopharma ecosystem: Biocon Biologics for insulin manufacturing, Phlow Corp. and VCU's Medicines for All Institute for end-to-end domestic production, AmerisourceBergen for distribution, CalRx for California's state-branded insulin initiative, and Breakthrough T1D plus the Helmsley Charitable Trust for funding. Civica is governed by hospital systems, payer representatives, and philanthropic organizations rather than equity investors, with leadership led since June 2022 by CEO Ned McCoy.

Name

Civica

Legal name

Civica, Inc.

Website

https://civicarx.org

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Civica is a nonprofit pharmaceutical company that supplies 70+ essential generic sterile injectable medications to 1,400+ U.S. hospitals through 60 health system members, and through its CivicaScript subsidiary distributes affordable outpatient generics and biosimilars to health plans, PBMs, and retail pharmacies.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Voluntary Health Organizations (813212), Civic and Social Organizations (81341), Social Advocacy Organizations (8133)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industry

Hospitals, Clinics & Charitable Healthcare Providers (BPAGACAB)

Keywords

• Generic pharmaceuticals
• Hospital drug supply
• Essential sterile injectables
• Biosimilar insulin
• Nonprofit drug manufacturing

Headquarters

HQ city

Lehi

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Hospital Membership and Drug Sales: Civica sells essential generic medications directly to member hospitals through long-term contracts. Hospitals pay membership fees and purchase medications at cost-plus pricing without hidden rebates or unfair markups.
2. Rural Hospital Membership Fees (Covered by Grant): For rural hospitals in the Civica Rural Hospital Program, per-bed membership fees are covered by the $3.2M Helmsley Charitable Trust grant. Civica waives annual purchase commitments for these hospitals.
3. Federal Government Contracts: Civica supplies essential generic medications to the U.S. Department of Veterans Affairs through a Federal Supply Schedule (FSS) contract, available to VA medical centers, outpatient clinics, and other federal agencies including the Department of Defense.
4. CivicaScript Outpatient Medications: CivicaScript sells affordable generic medicines and biosimilars to health plans, pharmacy benefit managers, and retail pharmacies. Products include insulin glargine at $45/box and ustekinumab biosimilar at $575-$985 per 12-week supply.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Civica is a nonprofit pharmaceutical company that manufactures and distributes essential sterile injectable generic medications to over 1,400 U.S. member hospitals through long-term contracts, and through its CivicaScript subsidiary provides affordable outpatient generics and biosimilars (including insulin glargine and ustekinumab biosimilars) to health plans, PBMs, and pharmacies at transparent maximum retail prices. The company operates its own U.S. manufacturing facility in Petersburg, Virginia and maintains six months of safety stock on essential medicines to prevent shortages and price gouging.

Product overview

Civica operates as a nonprofit pharmaceutical company with two main operating units: Civica Rx provides essential generic sterile injectable medications to member hospitals, while CivicaScript serves as the outpatient/retail arm offering affordable generic medicines and biosimilars. The company also includes Civica Foundation for philanthropy. The portfolio includes hospital-administered generics (over 70 essential medicines), biosimilar insulins (insulin glargine-yfgn), and biosimilars for chronic inflammatory conditions (ustekinumab-aauz). Civica focuses on addressing drug shortages and high prices through a mission-driven nonprofit model.

Differentiator

Problem solved

Functional benefit

Products and services

• Civica Rx Essential Hospital Generic Injectables Over 70 essential generic sterile injectable medications supplied directly to over 1,400 U.S. member hospitals through long-term market-stabilizing contracts at cost-plus pricing with six months of safety stock maintained.
• CivicaScript Outpatient Generics and Biosimilars Outpatient/retail arm of Civica selling affordable generic medicines and biosimilars to health plans, pharmacy benefit managers, and retail pharmacies at transparent Maximum Retail Prices.
• Insulin Glargine-yfgn Biosimilar long-acting insulin glargine indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus; interchangeable with Lantus; available in prefilled pens distributed nationwide through pharmacies.
• Ustekinumab-aauz Biosimilar ustekinumab product indicated for treatment of chronic inflammatory conditions including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis; interchangeable with Stelara.

Quantifiable outcome

• Saved patients and payers more than $16 million in 2025; nearly $44 million total savings since 2022
• +5 more outcomes

Named customers14 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

18 partnerships are on record, tiered core, major and minor.

• Biocon BiologicscoreOEM/ Whitelabel/ Licensing Partner · 16 October 2025Biocon Biologics expanded collaboration with Civica to manufacture and supply insulin glargine, which Civica markets under its own label. The partnership improves access and affordability for U.S. patients with diabetes, with Biocon manufacturing under its existing U.S. marketing approval and Civica distributing nationally (as CalRx in California).
• California / CalRxcoreStrategic or Co-development Partner · 1 January 2023California's CalRx biosimilar insulin initiative selected Civica as manufacturing partner. Civica insulin glargine will carry the CalRx brand in California pharmacies. This partnership aims to reduce insulin costs for California residents and influence market prices.
• Phlow Corp.coreStrategic or Co-development Partner · 21 January 2021Partnership with Phlow Corp. as part of a U.S. government-funded effort to manufacture essential medications from beginning to end, including APIs and finished dosage forms. Phlow leads the partnership which also includes VCU's Medicines for All Institute and AMPAC Fine Chemicals. Phlow executed a $354 million BARDA contract for manufacturing essential medications.
• Virginia Commonwealth University / Medicines for All InstitutecoreStrategic or Co-development Partner · 21 January 2021Partnership with VCU's Medicines for All Institute as part of the public-private manufacturing consortium aimed at creating a resilient regional biopharmaceutical ecosystem in Virginia.
• AmerisourceBergenmajorChannel Partner/ Reseller/ DistributorExclusive distribution partnership established with AmerisourceBergen for distributing Civica products.
• Groninger and SKANmajorTechnology or IntegrationEquipment and technology partners for Civica's Virginia manufacturing facility. Groninger and SKAN provide world-class fill-finish manufacturing technology for the sterile injectable facility.
• Blue Cross Blue Shield Association (BCBSA)coreGTM or Marketing PartnerBCBSA is a founding member and board participant in Civica. BCBSA and Blue Cross and Blue Shield Plans partner with CivicaScript through InnovateRx LLC (founded by 19 BCBS plans) to provide affordable medications and insulin at prices people can afford.
• Blue Cross of IdahomajorGTM or Marketing PartnerBlue Cross of Idaho represents the payer community on Civica's Board of Directors and works on pharmacy innovation initiatives.
• U.S. Department of Veterans AffairsmajorChannel Partner/ Reseller/ DistributorCivica awarded Federal Supply Schedule (FSS) contract by VA to supply essential generic medications via Pharmaceutical Prime Vendor program. Products available to VA medical centers, outpatient clinics, and other federal agencies including DoD.
• GeneSys BiologicsmajorStrategic or Co-development PartnerPartnership with GeneSys Biologics for affordable insulin development, orchestrated by Ned McCoy to bring Civica biosimilar insulins to market.
• Thermo FisherminorOEM/ Whitelabel/ Licensing PartnerContract manufacturing organization working with Civica to produce medications under Civica's ANDAs.
• HighmarkmajorGTM or Marketing PartnerHighmark is a founding member of CivicaScript and partners with Civica to provide lower-cost generic medications to members. Highmark members saved over $6 million on abiraterone acetate. Highmark also participates in CivicaRx insulin initiative.
• Virginia Talent Accelerator ProgrammajorImplementation/ SI/ Consulting PartnerVirginia Talent Accelerator Program partnered with Civica Rx to provide customized workforce training for approximately 300 positions at the Petersburg facility, in conjunction with Virginia Community College System.
• Inova HealthminorGTM or Marketing PartnerNew member joined Civica in 2025, representing healthcare system with significant hospital beds.
• Alaskan Native Tribal Health Consortium (ANTHC)minorGTM or Marketing PartnerNew member joined Civica in 2025, focused on tribal health services.
• AllinaminorGTM or Marketing PartnerNew member joined Civica in 2025, representing Minnesota-based health system.
• AveraminorGTM or Marketing PartnerNew member joined Civica in 2025, representing South Dakota-based health system.
• Dartmouth Mary Hitchcock MemorialminorGTM or Marketing PartnerNew member joined Civica in 2025, representing Dartmouth Health system.

Scale indicators21 records

Recent moves9 records

Expansion highlights7 records

Broad incumbents

• Sandoz (Novartis): World's largest generic pharmaceutical company with a substantial US sterile injectables and biosimilars franchise. Competes with both Civica Rx and CivicaScript (especially on biosimilars like ustekinumab and insulin glargine).
• Fresenius Kabi: Large global manufacturer of generic injectable pharmaceuticals and IV drugs supplied to US hospitals. Directly overlaps with Civica's sterile injectable portfolio and competes for the same hospital pharmacy contracts.
• Teva Pharmaceuticals: Largest generic drug manufacturer globally with significant US presence in sterile injectables, oral solids, and biosimilars. Direct competitor to Civica in essential medicines and to CivicaScript in outpatient generics.
• Hikma Pharmaceuticals: Global generic injectables manufacturer with a major US hospital injectables franchise. Comparable product overlap with Civica's hospital sterile injectable portfolio, though Hikma is a publicly traded for-profit manufacturer at much larger scale.
• Pfizer (Hospira): Through its Hospira acquisition, Pfizer operates one of the largest sterile injectable manufacturing networks in the US. Competes head-to-head with Civica in hospital injectables and is also a critical supply chain partner referenced in industry shortage dynamics.

Direct peers

• Apotex: Large Canadian-headquartered generic pharmaceutical manufacturer with significant US operations. Comparable in offering affordable generic medicines including injectables and oral solids to health systems.
• Phlow Corp. US-based public-private pharmaceutical manufacturer focused on essential medicines and API production, partnered with Civica in a $354M BARDA-funded consortium. Most directly comparable given shared mission of domestic essential-medicine manufacturing.
• Biocon Biologics: India-based biosimilars manufacturer that is a critical OEM partner to Civica for insulin glargine and competes in the same biosimilars end markets. Closely tied commercially through CivicaScript distribution.
• Amphastar Pharmaceuticals: US-based specialty injectable pharmaceutical company focusing on generic and branded injectables, including difficult-to-formulate products. Direct competitor in hospital injectable generics.
• Lannett (Bausch Health): US-focused generic pharmaceutical manufacturer producing a portfolio of hospital and retail generics, including sterile injectables. Comparable scale and channel mix to Civica.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/CivicaRx

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Civica